Norah A. Terrault, MD

Phone: 415-476-2227
UCSF Box: 0538
Email: norah.terrault@ucsf.edu
UCSF Profile

Project Sponsor Location(s) Topics Start End
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients Biotest Pharmaceuticals Corporation United States Infectious Disease, Pharmacology and Drug Treatment
A Phase 3 Evaluation of Daclatasvir and Sofosbuvir with Ribavirin in Cirrhotic Subjects with Genotype 3 Chronic Hepatitis C Infection Bristol-Myers Squibb Company United States Infectious Disease, Drug and Diagnostics Development
A Phase 2 open-label study in patients with recurrent Genotype 1 hepatitis C post-orthotopic liver transplant to explore the safety and efficacy of Simeprevir and Sofosbuvir with and without Ribavirin Janssen Research & Development, a J&J Co United States
Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) NIH National Institute of Diabetes and Digestive and Kidney Diseases United States Noncommunicable and/or Chronic Disease, Cancer/Oncology, Cardiovascular Disease
Protocol M12-999: Safety and Efficacy of the Combination of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Adult Liver Transplant Recipients with Genotype 1 Hepatitis C Virus (HCV) Infection AbbVie Inc. United States Drug and Diagnostics Development
A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic HCV for Use in the Peri-Operative Liver Transplantation Setting Gilead Sciences, Inc. United States Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment
Hepatitis B Research Network (HBRN): Natural History and Treatment Studies NIH National Institute of Diabetes and Digestive and Kidney Diseases United States Infectious Disease
A Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients with Chronic Hepatitis C Virus Genotype 1 - 6 Infection (MAGELLAN-2) AbbVie Inc. United States Infectious Disease, Drug and Diagnostics Development
Project Sponsor Location(s) Topics Start End
M13-099: Safety and Effect of ABT-450, Ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis (TURQUOISE-II) AbbVie Inc. United States Infectious Disease, Pharmacology and Drug Treatment
A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin for 24 weeks in Subjects with Recurrent Chronic HCV Post Liver Transplant Gilead Sciences, Inc. United States
Continuation of the Nonalcoholic Steatohepatitis Clinical Research Network: Noninvasive Radiological Diagnosis and Cardiovascular Impact of Nonalcoholic Fatty Liver Disease NIH National Institute of Diabetes and Digestive and Kidney Diseases United States Noncommunicable and/or Chronic Disease
Models for Optimal Liver Transplant Outcomes Mayo Foundation United States Surgery and Anesthesia
GS-US-337-0123 A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who have Advanced Liver Disease or are Post- Gilead Sciences, Inc. United States Infectious Disease
GS-US-342-1137: A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection and Child-Pugh Class B Cirrhosis Gilead Sciences, Inc. United States Pharmacology and Drug Treatment
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders Gilead Sciences, Inc. United States Infectious Disease, HIV/AIDS, Drug and Diagnostics Development
Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure United States